10
Participants
Start Date
March 19, 2019
Primary Completion Date
January 18, 2027
Study Completion Date
March 18, 2027
CD19 CAR-T CELLS
CD19 CAR-T cells will be administered after completion of the lymphodepletion chemotherapy.
Cyclophosphamide
Patients will receive lymphodepleting chemotherapy consisting of Cyclophosphamide 250 - 300 mg/m2/day IV(Day -5, Day -4, Day -3 ).
Fludarabine
Patients will receive lymphodepleting chemotherapy consisting of Fludarabine 25-30 mg/m2/day IV (Day -5, Day -4, Day -3 ).
RECRUITING
UKM Medical Centre, Bandar Tun Razak
Collaborators (1)
Gaia Science
OTHER
National University of Malaysia
OTHER